Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders · 2026-06 · 403 · 121385
DOI: 10.1016/j.jad.2026.121385 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026-06. Verfasst von Erica S Kaczmarek und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Toronto, Toronto, ON, Canada. Electronic address: erica.kaczmarek@uhn.ca. Hauptthemen laut MEDLINE: Psilocybin, Anhedonia, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain and Cognition Discovery Foundation.
Themen: Depression
Abstract (Originalsprache)
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary analysis aimed to evaluate the effects of psilocybin-assisted psychotherapy (PAP) on anhedonia severity in individuals with treatment-resistant depression (TRD). Participants (n = 30) with TRD and a primary diagnosis of Major Depressive Disorder or Bipolar II Disorder received at least one 25 mg dose of oral psilocybin with psychotherapy as part of a randomized, waitlist-controlled trial (NCT05029466). The primary outcome of the present secondary analysis was changes in anhedonia, measured by the Snaith-Hamilton Pleasure Scale (SHAPS). Exploratory analysis examined whether changes in anhedonia were mediated through changes in overall depression severity, measured by the Montgomery-Asberg Depression Rating Scale (MADRS). A mixed ANOVA, adjusted for sex and age, revealed a statistically significant reduction in SHAPS scores following PAP at the 2-week primary endpoint (F(8, 143.48) = 3.43, p = 0.001, n = 29) with clinically significant improvements observed at 3-month and 6-month secondary endpoints. Our findings from this preliminary analysis suggest that PAP may offer a promising intervention for addressing anhedonia in TRD, but further research with larger, placebo-controlled trials are needed to confirm these effects and elucidate potential mediators. This study adds to a growing body of evidence supporting the therapeutic potential of PAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada. Electronic address: erica.kaczmarek@uhn.ca.
- Department of Psychology, Neuropsychology Track, University of Windsor, Windsor, ON, Canada. Electronic address: rodrig23@uwindsor.ca.
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada. Electronic address: noah.chisamore@mail.utoronto.ca.
- Independent Practice, Ontario, Canada. Electronic address: zoe.doyle@uhn.ca.
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- Independent Practice, Ontario, Canada.
Förderung
- Brain and Cognition Discovery Foundation
Zitieren
APA
Kaczmarek, E. S., Rodrigues, N. B., Chisamore, N., Doyle, Z., Meshkat, S., Blainey, M. G., Brudner, R., Ali, S., Teopiz, K. M., McIntyre, R. S., & Rosenblat, J. D. (2026). Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression. Journal of Affective Disorders, 403, 121385. https://doi.org/10.1016/j.jad.2026.121385
Vancouver
Kaczmarek ES, Rodrigues NB, Chisamore N, Doyle Z, Meshkat S, Blainey MG, et al. Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression. Journal of Affective Disorders. 2026;403:121385. doi:10.1016/j.jad.2026.121385
BibTeX
@article{Kaczmarek2026,
author = {Kaczmarek, Erica S and Rodrigues, Nelson B and Chisamore, Noah and Doyle, Zoe and Meshkat, Shakila and Blainey, Marc G and Brudner, Ryan and Ali, Shaun and Teopiz, Kayla M and McIntyre, Roger S and Rosenblat, Joshua D},
title = {Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {403},
pages = {121385},
doi = {10.1016/j.jad.2026.121385}
}
EUVIMED